Pacemaker in the Beam Path: Starting VMAT Before the Physicist Returns
Mr. K, 74, has a right upper-lobe NSCLC (T2N2) and a dual-chamber Medtronic pacemaker implanted 3 years ago, last interrogated 6 months ago. The device sits in the right infraclavicular region; the 60 Gy/30-fraction VMAT PTV lies within 2.5 cm of the generator. The approved plan shows a maximum device dose of 3.8 Gy and a maximum lead dose of 2.9 Gy. Cardiology "cleared him for radiation" but did not specify a dose limit or a follow-up interval. The physicist is on leave, and the covering physicist asks you to start treatment as scheduled so the schedule isn't delayed.
1. What must be confirmed before the first fraction, and why is "cardiology cleared him" insufficient?
Read the worked answer
"Cleared" is a clinical statement, not a dosimetric one. Before the first fraction you need, in writing:
- The exact device model and manufacturer's recommended dose limits. Limits are device-specific (generator vs. leads, older vs. newer, ICD vs. pacemaker) and MRI-conditional status says nothing about radiation tolerance. A typical planning target is keeping the generator as low as reasonably achievable, frequently under ~2 Gy, but the manufacturer's documentation governs.
- A baseline interrogation (battery voltage, capture thresholds, sensing, lead impedance) so post-treatment changes can be attributed. Six-month-old data is not a baseline.
- A written cardiology/EP agreement on acceptable dose, on-device dose verification method, and the post-treatment interrogation schedule.
- Dosimetry that reports max dose to generator and to each lead separately, with the calculation grid fine enough to resolve a small high-Z object.
If the manufacturer's limit is lower than the 3.8 Gy/2.9 Gy in the approved plan, the plan must be revised. That is a physician and physics decision, not a scheduling decision - escalate rather than treat.
2. If the plan must be reworked, what planning and delivery changes reduce device dose?
Read the worked answer
Reduce dose by geometry first, then by technique:
- Avoid beam entry through the device: choose gantry angles/couch rotations so no field enters or exits through the generator, and add an arc-avoidance sector for the VMAT arcs. A sector of 30–40 degrees may cost little PTV coverage.
- Prefer photon energies and techniques that minimize secondary/neutron production (high-energy photon VMAT and proton therapy can produce neutrons; this is a separate concern from photon dose but relevant near CIEDs).
- Field shaping: block the device out of the beam path where PTV coverage permits, and re-evaluate whether the PTV margin can be met with a non-coplanar arrangement.
- Re-check, don't assume, the effect of bolus or shielding: lead over the generator can reduce dose but produces backscatter and skin dose; any shield must be modeled and measured.
- Recompute max device and lead dose on the revised plan before approval, and re-verify during delivery with in vivo dosimetry (MOSFET/TLD/OSL) at the first fraction, not after the course.
3. What monitoring applies during and after treatment?
Read the worked answer
During each fraction: continuous audio-visual observation, a staff member able to reach the patient within seconds, ECG monitoring for the first fraction and for any high-risk patient, and an emergency cart with a magnet available if the device is an ICD. Instruct the patient to report palpitations, dizziness, or syncope immediately, and stop treatment if symptoms occur.
Between fractions: weekly device check (or per EP's schedule), and in vivo dose measurement early so an unexpectedly high reading can still change the plan. After the course: a post-treatment interrogation, comparison to the baseline, and a documented communication to the EP/cardiology team. If the patient later needs an ICD or device replacement, note the radiation history for the implanting physician. Record cumulative maximum dose to the device in the chart so future courses are not planned blind.